Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The Stock for 1999(Polymedica)PLMD(Medical Supply Co.) -- Ignore unavailable to you. Want to Upgrade?

To: Abuckatatime who wrote (2201)	11/13/1998 7:56:00 PM
From: PAR	Respond to of 3414

Boy, with all this good/excellent PR and the insiders selling, then I must consider this a major red flag. Been burned BAD before and told myself never again.

To: Abuckatatime who wrote (2201)	11/15/1998 10:53:00 AM
From: Abuckatatime	Respond to of 3414

Oscar Gruss & Son, Inc revises revenue and earnings estimates upward. In a Nov 5 report, analyst W.R.Prather M.D. comments on PM's stronger than expected Q2 showing and adjusts his projections accordingly. (!) FY1999: EPS: $0.67 from prior $0.66 Revenues: $99 million from $92 million FY2000: EPS: $0.90 from $0.81 Revenues: $116 million from $103 million Continuing revenue gains from Liberty's expansion into the Type2 market as well as expanded market position of the AZO consumer line are cited as sources for PM's sustained growth. OG sets a 12 month price target of $15. IMO, that is a conservative number, especially considering eps growth alone, which is projected to exceed 30%.

To: Abuckatatime who wrote (2201)	11/15/1998 11:10:00 AM
From: Abuckatatime	Read Replies (2) \| Respond to of 3414

Branch Cabell also weighs in with a Nov 5 update. Analyst Michael Petusky - "…we are confident that trends in PM's business are getting even stronger." Noting that PM exceeded both their revenue and earnings estimates and that DSOs had dropped to levels not seen for several quarters, BC reiterated a strong buy rating on the stock and raised the 12 month price target to $17. Upward estimate revisions were again the order of the day - FY99 and FY2000 EPS estimates now $0.67 and $0.85, up 3 cents each from previous projections.